Compare RYAN & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAN | APGE |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.7B |
| IPO Year | 2021 | 2023 |
| Metric | RYAN | APGE |
|---|---|---|
| Price | $32.56 | $86.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $50.88 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 2.2M | 867.2K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,051,126,000.00 | N/A |
| Revenue This Year | $15.78 | N/A |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | $86.72 | ★ N/A |
| Revenue Growth | ★ 21.28 | N/A |
| 52 Week Low | $29.28 | $34.34 |
| 52 Week High | $68.70 | $95.32 |
| Indicator | RYAN | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 54.68 |
| Support Level | $31.50 | $73.70 |
| Resistance Level | $34.41 | $86.28 |
| Average True Range (ATR) | 1.50 | 4.94 |
| MACD | 0.08 | 0.78 |
| Stochastic Oscillator | 49.26 | 63.88 |
Ryan Specialty Holdings Inc is an international specialty insurance intermediary providing specialty products, solutions, and services for insurance brokers, agents, and carriers. The company offers wholesale insurance brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management. Its expertise spans property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits insurance, across traditional insurance and alternative risk solutions. The company operates in the United States and foreign markets, with the majority of revenue generated from the United States.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.